Sasaki, Shingo, Kazuyuki Daitoku, Atsushi Iwasa, and Shigeru Motomura. NO is involved in MCh-induced accentuated antagonism via type II PDE in the canine bloodperfused SA node. Am J Physiol Heart Circ Physiol 279: H2509-H2518, 2000.-The possible role of type II (cGMPstimulated cAMP hydrolysis) phosphodiesterase (PDE) in the accentuated antagonism of muscarinic effects on heart rate during ␤-stimulation via endogenous nitric oxide (NO) was evaluated. The canine isolated sinoatrial node preparation was cross circulated with arterial blood of a support dog. The sinoatrial rate of the preparation was 96 Ϯ 5 beats/min (n ϭ 16) at control. Methacholine (MCh; 0.01-1 g) injected into the right coronary artery in a bolus fashion caused dosedependent decreases in sinoatrial rate. Under an intra-arterial infusion of isoproterenol (1 M), resulting in ϳ50% increase in sinoatrial rate, MCh-induced decreases were markedly augmented from Ϫ18 Ϯ 3% to Ϫ44 Ϯ 4% at 0.3 mg
negative chronotropic effect; N G -nitro-L-arginine methyl ester; N G -monomethyl-L-arginine; 3-isobutyl-1-methylxanthine; amrinone; nitric oxide; phosphodiesterase; methacholine NITRIC OXIDE (NO) is known to play an important role as a modulator of many cellular processes in various tissues (23) . In particular, NO has been found to play physiological and pathophysiological roles in regulating cardiac functions, whereas various types of NO synthase (NOS) have been identified in cardiac myocytes, endocardium, intracardiac nerves, macrophages, and vascular endothelium (15) . The NADPH diaphorase technique and immunohistological approaches have demonstrated NOS-positive neurons in the atrial myocardium of guinea pig, in particular the sinoatrial (SA) node and atrioventricular (AV) node (17, 27) ; these latter tissues are generally considered to be densely innervated by postganglionic parasympathetic neurons.
Recently, it was reported that NO-mediated intracellular signaling pathways are involved in muscarinic cholinergic inhibition of heart rate and cardiac contraction (15) . In particular, Han and colleagues (9) (10) (11) substantially demonstrated in mammalian SA and AV node cells that NO modulated muscarinic cholinergic regulation of L-type Ca current (I Ca,L ) when intracellular cAMP was increased by ␤-adrenoceptor stimulation. This has been known as "accentuated antagonism," a term first introduced by Levy (20) for the sympathetic-parasympathetic interactions in the heart. In addition, Han et al. (10) also suggested that NO-mediated muscarinic cholinergic modulation of I Ca,L might be in part due to an activation of the type II cGMP-stimulated cAMP phosphodiesterase (PDE).
On the other hand, muscarinic inhibition of the SA node pacemaker activity results not only from inhibition of I Ca,L but also from activation of atrial muscarinic-activated K ϩ current (I K,ACh ) and an inhibition of hyperpolarization-activated inward pacemaker current (I f ) carried by Na ϩ (14) . The latter could predominate in the absence of ␤-adrenoceptor stimulation. In the absence of ␤-adrenoceptor stimulation, the physiological roles of endogenous NO, which is synthesized by cNOS, in muscarinic cholinergic nerves have been controversial (15, 29) . NOS inhibitors had little effect on I Ca,L , even in the presence of a muscarinic cholinergic agonist when intracellular cAMP was not elevated (1, 11) . Furthermore, NOS inhibitors also did not affect muscarinic stimulation of I K,ACh , which is known to be mediated by a pertussis toxin-sensitive G protein subunit (18) . Thus the effect of endogenous NO on I K,ACh also needs to be further assessed.
In addition to the pacemaker activity, it was demonstrated that NO also suppressed ␤-adrenoceptor-mediated increases in I Ca,L and contraction of ventricular myocytes, which are postulated to be mediated in large part by increases in intracellular cGMP (22) . However, the roles of NO in muscarinic inhibitions of ventricular functions have remained controversial even under ␤-adrenoceptor stimulation (1, 3, 12, 29, 30) .
In the present study, we attempted to clarify the following issues: 1) the possible roles of NO in the accentuated antagonism observed in muscarinic interventions under ␤-adrenoceptor stimulation, 2) possible roles of type II PDE, and 3) potential differences between chronotropism and inotropism in relation to the interaction between NO regulation and parasympathetic innervation to the cardiac tissues. For these purposes, we used canine isolated blood-perfused SA node and papillary muscle (PM) preparations, in which drugs were administered directly into each nutrient coronary artery. The negative chronotropic and inotropic effects of methacholine (MCh), a long-acting analog of ACh, were compared under similar physiological conditions.
METHODS

Isolated, Blood-Perfused SA Node and PM Preparations
Experiments were carried out on the canine isolated SA node (19) , and PM (8) preparations were cross circulated with heparinized arterial blood of a support dog (24, 25) . The hearts were obtained from mongrel dogs of either sex weighing 8-12 kg. The animals were anesthetized with pentobarbital sodium (30 mg/kg iv), given heparin calcium (500 U/kg iv), and exsanguinated. The heart was rapidly excised and plunged into cold Tyrode solution kept at ϳ4°C.
The SA node preparation consists of the entire right atrium in which the sinus node artery was cannulated through the right coronary artery. The SA rate of the spontaneous beating preparation was measured with a cardiotachograph (1321; NEC San-ei Instruments, Tokyo, Japan) triggered by bipolar atrial electrograms recorded from the atrial epicardium close to the SA node.
The PM preparation consists of the anterior papillary muscle of the right ventricle attached to the interventricular septum. The cannulated anterior septal artery supplying to the PM was perfused by the support dog. The PM preparation was electrically driven at a fixed basal cycle length of 500 ms by a stimulator (DHM-226-3; Dia Medical, Tokyo, Japan) and an isolation unit (DSP-110; Dia Medical) with rectangular pulses of 1-3 V (ϳ20% above the threshold voltage) and 5-ms duration through bipolar stimulating electrodes sutured onto the endocardium of the ventricular septum close to the base of the PM. Developed tension of the PM preloaded with a 2-g weight was measured isometrically using a forcedisplacement transducer (DRM-T200; Dia Medical) and an amplifier (DRM-T20; Dia Medical).
Cross Circulation
The SA node and PM preparations were each placed in double-wall glass jackets maintained at 38°C by circulating warm water. Both preparations were simultaneously cross circulated with the heparinized arterial blood of a support dog through the cannulated arteries at a constant perfusion pressure of 120 mmHg with a Harvard peristaltic pump and a Starling pneumatic resistance placed parallel to the perfusion system. Venous blood from each preparation and excess blood passing through the pneumatic resistance were collected in the blood reservoir and returned to the support dog through the jugular vein. The coronary blood flow rate in each cannulated artery was measured using an electromagnetic flowmeter (MFV-1100, Nihon Kohden, Tokyo, Japan) and 2-mm cannulating flow probes.
Adult mongrel dogs of either sex, weighing 12-18 kg, used as support dogs, were anesthetized with an initial intravenous dose of 30 mg/kg of pentobarbital sodium and maintained with a continuous intravenous infusion of 5 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 at a rate of 10 ml/h by using an infusion pump (model STC-521, Terumo, Tokyo, Japan). The animals received an initial dose of 500 U/kg heparin calcium, followed by 200 U/kg every hour. Respiration was controlled using an animal respirator (SN-3041, Shinano Instruments, Tokyo, Japan). Systemic blood pressure at the femoral artery and heart rate triggered by the R wave of the limb II lead of the electrocardiogram were monitored continuously with a polygraph (361-6, NEC San-ei Instruments). Blood pressure and heart rate of the support dog were kept constant during experiments. Mean blood pressure and heart rate were 97 Ϯ 6 mmHg and 117 Ϯ 8 beats/min at the beginning of the protocol and 95 Ϯ 5 mmHg and 109 Ϯ 7 beats/min 2 h after the protocol, respectively.
Experimental Protocol
Protocol 1. To confirm that endothelium-dependent coronary vasodilatation was intact, the effects of ACh (0.01-1g), which is known as an endothelium-dependent vasodilator, and MCh (0.01-1 g), which is a long-acting analog of ACh, on the coronary blood flow, SA rate, and developed tension were compared by injecting them into each nutrient artery of the preparation with a microsyringe (Terumo, Tokyo, Japan). Peak changes in each parameter were measured and expressed as percentages of corresponding basal predrug values. Dose-response curves for negative chronotropic, negative inotropic, and coronary vasodilator effects of MCh and ACh were obtained, respectively.
Protocol 2. For ␤-adrenoceptor stimulation, isoproterenol (Iso) was continuously infused into each nutrient artery to produce a steady-state concentration of 1 M in the arterial blood, which produced an ϳ50% increase in SA rate and a 100% increase in developed tension, respectively. The blood concentration of Iso at 1 M was calculated by measuring the rate of coronary blood flow and adjusting the concentration of Iso in the syringe for a continuous infusion at a rate of 0.1 ml/min into the nutrient artery. During the infusion, the coronary blood flow was essentially unchanged. As a result, the infusion rate to achieve a target concentration for Iso of 1 M in the arterial blood could be reliably calculated.
In the presence of ␤-adrenoceptor stimulation, MCh (0.01-1 g) was administrated into each nutrient artery of the preparations, and dose-response curves for negative chronotropic and negative inotropic effects were obtained as percentages of the corresponding pre-MCh values that had been enhanced by Iso.
After the parameters of the preparations returned to stable states, N G -nitro-L-arginine methyl ester (L-NAME), a nonselective NOS inhibitor, was infused to give a concentration of 100 M in arterial blood, calculated and adjusted according to the coronary blood flow rate and drug concentration in the syringe. Iso (1 M in arterial blood) was then infused again and subsequently MCh was injected again, and dose-response curves for negative chronotropic and negative inotropic effects were obtained.
Similarly, N G -monomethyl-L-arginine (L-NMMA), another nonselective NOS inhibitor, was infused into the right coro-nary artery (100 M in arterial blood), and then the negative chronotropic effects of MCh were evaluated during Iso (1 M) infusion in the SA node preparation.
Protocol 3. Likewise, MCh (0.01-1g) was administrated into the right coronary artery of the SA node preparation in the presence of ␤-adrenoceptor stimulation with 1 M of Iso, and the dose-response curve for negative chronotropic effects of MCh was obtained again. After the SA rate and coronary blood flow of the SA node preparation returned to stable baseline states, 3-isobutyl-1-methylxanthine (IBMX), which is a nonspecific PDE inhibitor, or amrinone, which is a selective PDE III inhibitor, were infused to give a concentration of 20 M, calculated and adjusted according to the coronary blood flow rate and drug concentration in the syringe. Iso (1 M in arterial blood) was then infused, subsequently MCh was injected again, and dose-response curves for negative chronotropic effects of MCh were obtained, respectively.
Protocol 4. In contrast to protocol 2, influences of L-NAME (100 M in arterial blood) or L-arginine (100 M in arterial blood), a substrate for NOS, on the negative chronotropic and inotropic effects of MCh were determined in the absence of ␤-adrenoceptor stimulation, respectively. Thereafter, L-arginine was infused after an infusion of L-NAME, and the dose-response curves for negative chronotropic and negative inotropic effects of MCh were obtained again.
Drugs
Drugs used were MCh chloride (Sigma, St. Louis, MO), Iso hydrochloride (Nikken Kayaku, Tokyo, Japan), L-NAME (Wako, Osaka, Japan), IBMX (Wako, Osaka, Japan), amrinone (Yamanouchi, Tokyo, Japan), L-NMMA (Wako), and L-arginine (Wako).
Statistics
All values in text are arithmetic means Ϯ SE. Statistical analyses were performed using ANOVA. When F statistics were significantly larger than the appropriate critical values, post hoc t-tests were performed. Simultaneous multiple comparisons were then done by the Bonferroni methods (28) . When P values were Ͻ0.05, the difference was taken to be significant.
Ethics
The experiments were performed in accordance with guidelines for animal experimentation of Hirosaki University.
RESULTS
Comparison of the Effects of MCh and ACh in the SA Node and PM Preparations
In the SA node preparations, the basal SA rate was 96 Ϯ 8 beats/min (n ϭ 8), and the basal coronary blood flow through the right coronary artery was 3.0 Ϯ 0.3 ml/min. MCh or ACh in a dose range of 0.01-1 g injected into the right coronary artery in a bolus fashion produced dose-dependent decreases in SA rate (negative chronotropic effects). The maximal negative chronotropic effect of MCh was comparable with that of ACh. The doses that decreased the SA rate by 20% were 0.30 Ϯ 0.10 g for MCh and 0.47 Ϯ 0.15 g for ACh (n ϭ 8), respectively.
In the PM preparations, after ventricular fibrillation was terminated ϳ1 h after the start of cross circulation, the basal developed tension was 6.5 Ϯ 0.2 g, and the basal coronary blood flow through the anterior septal artery was 5.2 Ϯ 0.3 ml/min (n ϭ 8). When MCh or ACh in a dose range of 0.01-1 g was injected into the anterior septal artery, dose-dependent decreases of developed tension (negative inotropic effects) and increases in coronary blood flow rate through the anterior septal artery (coronary vasodilator effects) were produced. The maximal negative inotropic effect and coronary vasodilator effect of MCh were comparable with those of ACh. The doses that decreased the developed tension by 20% were 0.75 Ϯ 0.20 g for MCh and 0.54 Ϯ 0.15 g for ACh (n ϭ 8), and the doses that increased the coronary blood flow rate through the anterior septal artery by 20% were 0.022 Ϯ 0.009 g for MCh and 0.011 Ϯ 0.005 g for ACh (n ϭ 8), respectively. There were no significant differences between the doses of MCh and ACh.
Accentuated Antagonisms of MCh-Induced Negative Chronotropic Effects in the SA Node and Negative Inotropic Effects in the PM Preparations
When Iso was continuously infused into the nutrient coronary artery to give a calculated blood concentration of 1 M (see METHODS), the SA rate was increased from 92 Ϯ 3 beats/min to 158 Ϯ 6 beats/min (n ϭ 8). As shown in Fig. 1, A and B, when MCh was injected into the right coronary artery in the presence of Iso, the SA rate was slowed markedly more compared with the bradycardia observed in the absence of Iso. In addition to the augmented decreases in SA rate, the duration of the negative chronotropic effect was prolonged in the case of administration of a larger dose of MCh in the presence of Iso. Similarly, as shown in Fig. 2, A and B, decreases in the developed tension produced by MCh were augmented in the presence of Iso compared with those in the absence of Iso.
In Fig. 3A , the averaged dose-response curves are shown for the negative chronotropic effects of MCh in the absence and presence of Iso. Quantitatively, for example, the decrease in SA rate, which was 18 Ϯ 3% at 0.3 g of MCh in the absence of Iso, was significantly augmented to 44 Ϯ 4% at the same dose of MCh in the presence of Iso (n ϭ 8, P Ͻ 0.01). The averaged doseresponse curves for the negative inotropic effect of MCh are shown in Fig. 3B . At control, the basal developed tension was 7.0 Ϯ 0.3 g (n ϭ 8), and the decrease in developed tension was 15 Ϯ 1% at 0.3 g of MCh. In the presence of Iso (1 M), the pre-MCh developed tension was increased to 17.0 Ϯ 0.5 g (n ϭ 8), and the decrease in developed tension was significantly enhanced to 31 Ϯ 4% at the same dose of MCh (n ϭ 8, P Ͻ 0.01).
These phenomena have been termed "accentuated antagonism" by Levy (20) . In both preparations, however, MCh-induced increases in coronary blood flow were not enhanced in the presence of Iso. The increases were 18 Ϯ 2% (n ϭ 8) in the SA node and 28 Ϯ 3% (n ϭ 8) in the PM preparations at 0.3 g of MCh in the absence of Iso, whereas increases were 17 Ϯ 3 (n ϭ 8) and 30 Ϯ 5% (n ϭ 8) in the presence of Iso, respectively.
Effects of NOS Inhibition on Accentuated Antagonisms of MCh-Induced Negative Chronotropic and Inotropic Effects
In the SA node preparations, when the SA rate returned to the basal level, at least 1 h after cessation of Iso infusion, a continuous intracoronary infusion of L-NAME was started, calculated as 100 M in blood. After an infusion of L-NAME alone, the SA rate was slightly reduced from 92 Ϯ 2 to 90 Ϯ 2 beats/min (n ϭ 8, P Ͻ 0.05), and the coronary blood flow was similarly reduced from 3.1 Ϯ 0.4 to 2.9 Ϯ 0.4 ml/min (n ϭ 8, P Ͻ 0.05). After treatment with L-NAME, the augmented negative chronotropic effect of MCh in the presence of Iso (Fig. 1B) was markedly suppressed, as shown in Fig. 1C . Quantitatively, as shown in Fig. 3A , the MCh-induced (0.3 g) decrease in SA rate in the presence of Iso was significantly suppressed from 44 Ϯ 4 (Iso alone) to 29 Ϯ 3% after pretreatment of L-NAME (100 M) (n ϭ 8, P Ͻ 0.01). The increases in coronary blood flow induced by MCh were not significantly affected.
By contrast, in the PM preparation, the magnitude of the MCh-induced negative inotropic effects in the presence of Iso were not affected by L-NAME (Fig. 2C) . As shown in Fig. 3B , the averaged decreases in developed tension in the presence of Iso (1 M) were 31 Ϯ 4 and 32 Ϯ 4% before and after pretreatment of L-NAME (100 M), respectively. There was no significant difference between them. Although the coronary blood flow through the anterior septal artery of the PM preparation was also slightly reduced from 5.6 Ϯ 0.8 to 4.8 Ϯ 0.8 ml/min (n ϭ 8, P Ͻ 0.01) after L-NAME (100 M), the increases in coronary blood flow induced by MCh were not significantly changed.
Identical results were obtained when L-NMMA was used instead of L-NAME. Augmented negative chronotropic effects of MCh in the presence of Iso were similarly suppressed after an infusion of L-NMMA. Figure  4 shows averaged dose-response curves for the negative chronotropic effects of MCh in the absence and presence of Iso and for Iso ϩ L-NMMA. At control, the basal SA rate was 94 Ϯ 6 beats/min (n ϭ 6), and 0.3 g of MCh decreased the SA rate 19 Ϯ 3%. In the presence of Iso (1 M), the pre-MCh SA rate increased to 150 Ϯ 9 beats/min (n ϭ 6), and the decrease in SA rate was significantly augmented to 42 Ϯ 5% at the same dose under an increased adrenergic tone with isoproterenol (Iso; 1 M, calculated in arterial blood), MCh-induced negative chronotropic effects were markedly augmented. C: after a preinfusion of N G -nitro-L-arginine methyl ester (L-NAME; 100 M, calculated in arterial blood), augmented MCh-induced negative chronotropic effects were suppressed. Note the ordinate, in which SA rates were shifted to higher rate in the presence of Iso before injections of MCh (B, C).
Fig. 2. A typical experiment of the effects of NOS inhibition on accentuated antagonism of MCh in the papillary muscle (PM) preparation. A: negative inotropic effects of MCh at control (in the absence of ␤-adrenoceptor stimulation). B:
under an increased adrenergic tone with Iso (1 M calculated), MCh-induced negative inotropic effects were markedly augmented. C: after preinfusion of L-NAME (100 M calculated), enhanced MCh-induced negative inotropic effects were not affected even in the presence of ␤-adrenoceptor stimulation. Note the ordinate, whose scale was reduced to approximately one-half during Iso infusion (B, C). of MCh. After treatment of L-NMMA (100 M), the augmented decrease in SA rate was significantly suppressed to 25 Ϯ 3% at 0.3 g of MCh in the presence of Iso (n ϭ 6, P Ͻ 0.01).
Effects of PDE Inhibition on Accentuated Antagonisms of MCh-Induced Negative Chronotropic Effect
In the SA node preparation, after confirmation of the accentuated antagonism and the SA rate had returned to the basal level, at least 1 h after cessation of Iso infusion, a continuous intracoronary infusion of IBMX or amrinone (20 M in arterial blood) was started. Although an infusion of either IBMX or amrinone did not significantly affect the SA rate, the SA rate was almost doubled by a subsequent infusion of Iso from 95 Ϯ 3 to 175 Ϯ 8 beats/min. As shown in Fig. 5 , the augmented negative chronotropic effects of MCh in the presence of Iso were significantly suppressed by IBMX, but not affected by amrinone, even in the presence of Iso. For example, at 0.3 g of MCh, decreases in SA rate were 17 Ϯ 4% at control, 23 Ϯ 5% in the presence of Iso, 14 Ϯ 1% in the presence of Iso ϩ IBMX, and 20 Ϯ 3% in the presence of Iso ϩ amrinone, respectively.
Effects of NOS Inhibition on the Negative Chronotropic and Inotropic Effects of MCh in the Absence of ␤-Adrenoceptor Stimulation
In contrast to the results in the presence of Iso, L-NAME alone did not suppress MCh-induced negative chronotropic effects in the absence of Iso, as shown in Fig. 6 . However, when excess L-arginine (100 M) was infused subsequently to L-NAME, MCh-induced negative chronotropic effects were suppressed in six of eight dogs (Fig. 6D) , although increases in coronary blood flow rate induced by MCh were not significantly changed. In the other two dogs, no changes were induced by MCh. Nonetheless, when L-arginine alone was infused in each preparation, excess L-arginine per se did not affect the MCh-induced negative chronotropic effects (Fig. 6C) . Similarly, in the PM preparations, MCh-induced negative inotropic effect was also not affected by NOS inhibition in the absence of Iso (Fig. 7) . Furthermore, excess L-arginine alone did not affect the MCh-induced negative inotropic effects (Fig.  7C) . In both preparations, excess L-arginine alone did not affect the coronary blood flow rate.
The averaged dose-response curves for negative chronotropic and inotropic effects of MCh in the absence of Iso are shown in Fig. 8 . In both preparations, L-NAME alone or excess L-arginine per se did not affect the MCh-induced negative chronotropic and inotropic effects in the absence of Iso (Fig. 8, A and B) . However, the negative chronotropic effects induced by larger doses of MCh were suppressed by excess L-arginine infused subsequently to L-NAME (Fig. 8A) . On the other hand, the MCh-induced negative inotropic effects were not affected by L-arginine ϩ L-NAME (Fig. 8B) .
DISCUSSION
In the present study, applying the canine isolated, blood-perfused SA node and PM preparations, we demonstrated the following findings: 1) MCh-induced muscarinic cholinergic interventions in the SA node pacemaker activity can be modulated by endogenous NO at least in the presence of ␤-adrenoceptor stimulation; 2) under an increased adrenergic tone, accentuated antagonism of MCh-induced negative chronotropic effect can be partially modulated by endogenous NO via an activation of the type II cGMP-stimulated cAMP PDE; 3) however, in the absence of ␤-adrenoceptor stimulation, NO does not play an important role in MChinduced muscarinic cholinergic interventions in heart rate; and 4) on the other hand, muscarinic cholinergic interventions in ventricular contractility cannot be modulated by endogenous NO, even in the presence of ␤-adrenoceptor stimulation.
In the present experiments, L-NAME was mainly used for inhibition of NO synthase. Certainly, L-NAME maneuver has a wide variety of other actions as reviewed by Campbell and Harder (4). In addition, as reported by Buxton et al. (5), L-NAME has an antimuscarinic action, which could have an influence on the effects of MCh. According to Buxton et al. (5), however, L-NMMA does not possess an atropine-like action. Therefore, the experiment was repeated using L-NMMA instead of L-NAME, and almost identical qualitative results were obtained, as shown in Fig. 4 . Thus the results obtained by using L-NAME as well as L-NMMA were equally reliable under the conditions of the present study.
In the present study, the magnitude of accentuated antagonism was expressed as a percentage of pre-MCh values. This means that pre-MCh values had been increased by ␤-adrenoceptor stimulation with or without PDE inhibition and before or after NOS inhibition. Thus the larger percentage decrease in SA rate in the presence of ␤-adrenoceptor stimulation means a further large decrease in actual SA rate, that is, accentuated antagonism. Even in the actual values, however, L-NAME did not affect the accentuated antagonism of MCh-induced negative inotropic effect. On the other hand, the duration of the negative chronotropic effects in accentuated antagonism at larger doses of MCh might be due to the shift of the predominant pacemaker within the SA node, because the negative chronotropic effect abruptly terminated and then gradually returned to the basal value. Such hypothetical changes would likely be similar to the observations for the predominant pacemaker shift in the AV junctional area (26) . The SA node is usually under the tonic influence of both divisions of the autonomic nervous system in the mammalian heart. Ordinarily, parasympathetic tone predominates over sympathetic tone at the SA node, but changes in heart rate are evoked by the interaction of both divisions. Muscarinic inhibition of SA nodal automaticity primarily results from inhibition of I f and I Ca,L and an activation of I K,ACh (14) . Muscarinic receptors, when stimulated, are coupled with the pertussis toxin-sensitive G proteins; the latter are heterotrimers consisting of ␣-, ␤-, and ␥-subunits and are postulated to be the critical components for activating I Ca and I K,ACh . Under an increased adrenergic tone, it has been demonstrated that ACh can antagonize the activation of adenylyl cyclase via mechanisms involving G proteins (probably G i and/or G o ) and that it can inhibit Ca channel phosphorylation, thereby decreasing I Ca (13) . In this case, an inhibitory effect of ACh on ␤-adrenoceptor activation is mainly modulated by interactions between the ␣-subunit of G i (G i ␣) and adenylyl cyclase, resulting in a decrease in cAMP level (4) .
It has been suggested in various species that NO donors release NO and increase the intracellular cGMP levels by enhancing guanylyl cyclase activity in cardiac myocytes, and thereby modulate the activity of I Ca,L . For example, in frog and guinea pig ventricular cells, sodium nitroprusside (in M concentration), similar to cGMP, had little effect in altering the amplitude of I Ca,L in the absence of cAMP elevation (22) . When the intracellular cAMP concentration was elevated, however, sodium nitroprusside administration inhibited I Ca,L , which was attributed to cGMP-stimulated PDE in the frog and to cGMP-activation of cGMPdependent protein kinase in the guinea pig (22) . In mammalian hearts, it was demonstrated that type II (cGMP stimulated) and type III (cGMP inhibited) PDE are primarily localized in cardiac tissue (2) . In this connection, in the present study, we demonstrated that IBMX, a nonspecific PDE inhibitor, suppressed the accentuated antagonism of MCh-induced negative chronotropic effect, but amrinone, a selective PDE III inhibitor, did not. Therefore, our present results indirectly, but strongly, suggested that the accentuated antagonism of MCh-induced negative chronotropic effect could be modulated by type II PDE, which is stimulated by cGMP produced by endogenous NO via activation of cGMP-dependent protein kinase.
On the other hand, in the absence of ␤-adrenoceptor stimulation, the physiological role of the NO-mediated signaling pathway in the SA node has been controversial. At a baseline stable state, NO did not play a significant role in parasympathetic modulation of even the SA node, because L-NAME did not affect heart rate at all. However, when excess L-arginine was infused, this intracellular signaling pathway began to operate in parasympathetic modulation of the SA node, and thereafter L-NAME began to inhibit MCh-induced negative chronotropic effects. Hence, even in the absence of ␤-adrenoceptor stimulation, excess L-arginine may play a key role in modulation of NO-mediated muscarinic cholinergic transmission.
As discussed above, the muscarinic receptors are also coupled with the ACh-regulated K ϩ channels by the ␤-and ␥-subunit (G␤␥) of pertussis toxin-sensitive G protein and do not require intracellular buildup of second messengers, mainly cAMP, to exert beat-bybeat control of heart rate (21). Hence, if endogenous NO modulates heart rate through the NO-mediated muscarinic cholinergic signaling pathway even in a basal condition, it should affect not only I Ca,L but also I K,G , i.e., I K,ACh . In the present study, however, we demonstrated that even the MCh-induced negative chronotropic effect was not influenced significantly by pharmacological interventions to NO synthesis in the absence of ␤-adrenoceptor stimulation. These results may imply that endogenous NO-mediated intracellular signaling does not intervene to G␤␥, which mediates the activity of ACh-regulated K ϩ channels. Furthermore, it has remained controversial whether NO donors affect the I K,ACh that directly binds G␤␥. Recently, we investigated the effects of an NO donor, nitroglycerin, on MCh-induced negative chronotropic and inotropic effects, but we could not demonstrate any direct interactions between the NO donor and muscarinic cholinergic interventions in the absence of ␤-adrenoceptor stimulation. These results indicate that endogenous NO may have different actions than exogenous NO in the muscarinic cholinergic modulation of the SA node pacemaker activity. Thus, in the heart, cNOS may exert different actions from inducible NOS for pacemaker activity.
In the present study, augmented MCh-induced negative chronotropic effect was suppressed substantially by NOS inhibition with L-NAME, but the enhanced MCh-induced negative inotropic effect was not affected. These results have convinced us of the existence of an NO-mediated signaling pathway at least in the SA node, as already discussed, and suggest that this pathway may have tissue specificity. Roles of NO in muscarinic inhibition of ventricular functions have been controversial even in the presence of ␤-adrenoceptor stimulation. It has been reported in an in vivo study (12) that NO mediates vagal inhibition of the inotropic response to ␤-adrenergic stimulation. However, NO did not affect the muscarinic inhibition of cAMP-regulated ion (Cl Ϫ ) channels in ventricular myocytes (30) and did not elicit an acute negative inotropic effect in unstimulated ventricular muscle (29) . This tissue specificity of the action might be partly due to the difference of distribution of M2-receptors between the atrium and the ventricle. Parasympathetic nerves were shown to densely innervate the atria, in particular the SA node in dogs, whereas the ventricles are sparsely innervated by the vagi, although species differences do exist in the distribution of M2-receptors (7, 16) . This difference of parasympathetic innervation could be attributed to the heterogeneity in the distribution of M2-receptors in the heart.
In conclusion, NO-mediated modulation of muscarinic cholinergic transmission was clearly demonstrated only in the case of augmented MCh-induced negative chronotropic effect under an increased adrenergic tone, when I Ca , I Ca,L , or T-type Ca current could be enhanced by ␤-adrenoceptor stimulation. These modulations were mediated via an activation of the type II cGMP-stimulated cAMP PDE. In the basal condition, however, the MCh-induced negative chronotropic effect, which could be mainly mediated by activation of I K,G , i.e., I K,ACh , might not be modulated by endogenous NO. Consequently, expression of endogenous NO-mediated actions might be largely dependent on both the presence of ␤-adrenoceptor stimulation and the magnitude of parasympathetic cholinergic innervation, which predominates in the SA node.
